Appears to be a Weirdly Figure Standing In A Creepy White Room. Unknown Siren Head.

3 天之前 · Creating a new page for a phase that doesn't have one yet.Why? The Name Explain Himself

This phase/article is controversial against the community and is the cause of edit wars. Please do not add information to this page unless it's from a reliable source.

2024年4月7日 · EOS-984 is a potential first-in-class small molecule targeting the equilibrative nucleoside transporter 1 (ENT1) designed to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation.

EOS-984: Completed enrollment of the first dose cohort and continued advancement in the dose escalation of the Phase 1 trial in advanced malignancies. Topline data from the Phase 1 trial are anticipated in late 2024....R&D expenses were $30.6 million for the quarter ended September 30, 2023, as compared to $23.9 million for the same quarter of ...

2024年4月7日 · EOS-984 is a potential first-in-class small molecule targeting the equilibrative nucleoside transporter 1 (ENT1) designed to inhibit the immunosuppressive activity of adenosine and restore immune...

For ENT1, a channel enabling the flow of immunosuppressive adenosine into T cells, we are advancing EOS-984. For TREM2, a receptor enabling the creation of the hostile tumor microenvironment, we are advancing EOS-215.

2024年12月4日 · EOS-984 is under development for the treatment of advanced solid tumors. The drug candidate is administered through oral route. It acts by targeting equilibrative nucleoside …

EOS-984: potential first-in-class small molecule inhibiting ENT1, a dominant transporter of adenosine on lymphocytes involved in T cell metabolism, expansion, effector function, and survival Topline data from the Phase 1 trial anticipated in the second half of 2024.

EOS-984 is a potential first-in-class small molecule in oncology inhibiting ENT1 that we are developing to reverse suppression of the immune system’s response and restore T cell proliferation in the tumor microenvironment.